What is a CAR-T cell and how can BIOTEM support you?
|Chimeric Antigen Receptor-T cell (or CAR-T Cell) are T lymphocytes collected from the patient and genetically modified with viral vector to express on their surface specific receptors/antibodies directed against tumor markers. In addition, these modified cells also express different domains in order to stimulate the immune response and initiate defense cascades.
Morever, there are 4 generations of CAR-T that change according to the intracellular domains. A 5th generation is even being studied. While the first clinical trial results were published in 2010, the first CAR-T based treatment was approved by the FDA in 2017 and commercialized by Novartis.
Consequently, this technology is one of the innovative solutions for personalized treatment of patients in therapeutic escape and opens the way to targeted therapies on a large number of diseases such as cancer.